Senti Biosciences, Inc. has announced that its CEO, Timothy Lu, participated in Nasdaq's Amplify Spotlight Series, where he discussed the company's proprietary Gene Circuit platform aimed at ...
– SENTI-202 is a potential first-in-class off-the-shelf CAR-NK cell therapy using Logic Gated Gene Circuits to selectively target cancer cells while sparing healthy bone marrow cells – The Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results